ArticleScientific reports2025
Therapeutic effect of exogenous tumor necrosis factor-stimulating protein 6 intervention on lung injury in newborn rats by intrauterine infection.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To investigate the therapeutic effect of exogenous tumor necrosis factor-stimulating protein 6(TSG-6) on lung injury in newborn rats induced by intrauterine infection, and to analyze its underlying mechanism. Twelve pregnant rats were randomly divided into a blank control group, a negative control group, a model group, and a TSG-6 treatment group. The blank control group was not modeled. The negative control group was injected with normal saline (NS) intraperitoneally on gestation day (E)14, and the remaining two groups were intraperitoneally injected with lipopolysaccharide at 0.6 mg/kg × body weight(kg) on E14 to establish the intrauterine infection model. The negative control and model groups were injected with NS via the tail vein on E16, and the TSG-6 treatment group was injected with TSG-6 at 0.25 mg/kg × body weight(kg) via the tail vein on E16. After delivery, the placentas of pregnant rats and the right lungs of newborn rats on postnatal day (P) 3, 7, and 14 were stained with hematoxylin-eosin to observe the inflammatory infiltration of placentas, the pathology of the lungs, and the radical alveolar count (RAC) was performed. The left lung tissues of newborn rats were collected on P3, P7d, and P14. Using Enzyme-linked immunosorbent assay (ELISA) kits to measure the levels of TSG-6, tumor necrosis factor-α(TNF-α), vascular endothelial growth factor (VEGF), and Interleukin-6 (IL-6) in lung tissues of newborn rats. Compared with the model group, the growth of the control group and the TSG-6 treatment group was better, the bronchial epithelial structure of the control and TSG-6 treatment group was intact, and the epithelial cells were normal and closely arranged. The levels of RAC, VEGF, and TSG-6 in the TSG-6 treatment group were significantly increased, and the levels of IL-6 and TNF-α were significantly decreased at the early stage of life compared with the model group; the differences were statistically significant (P < 0.05). TSG-6 intervention can reduce the inflammatory response of pregnant rats with intrauterine infection and significantly improve the pathological degree of lung injury in newborn rats caused by intrauterine infection. Its mechanism may be related to promoting the increase of TSG-6 and VEGF levels, regulating the balance of inflammatory factors and promoting tissue repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.